Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575168 | 1.00 | NAAA (0.36) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4912188 | 1.00 | NAAA (0.36) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4912199 | 1.00 | NAAA (0.36) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4862984 | 0.92 | NAAA (0.37) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4861959 | 0.82 | SIGMAR1 (0.39) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL21028938 | 0.80 | CTSL (0.41) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL22906947 | 0.80 | CTSL (0.41) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL21029509 | 0.80 | CTSL (0.41) | NAAAOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4862979 | 0.80 | TSHR (0.38) | — | |
| SCHEMBL14107808 | 0.79 | CTSL (0.37) | NAAAOPRM1OPRL1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | NAAA 713/4885OPRM1 401/4885OPRL1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.